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Objectives: Ministry of Health, Labour and Welfare of Japan aims for the introduc-
tion of Health Technology Assessment in FY2016. Compared to foreign countries, a 
lack of resources for conducting the analysis has been pointed out in Japan. However, 
pharmaceutical and medical device industries are urged to seek practical approaches 
utilizing best available resources. The objective of this study was to review articles 
for cost-effectiveness analysis of major depression disease (MDD) and to evaluate 
analytical approaches that can be applied to Japanese environment. MethOds: The 
literature search was conducted in MEDLINE and JDream III. Inclusion criteria are 
studies of 1) treatment for MDD, 2) cost-effectiveness analysis (CEA), 3) published in 
the past 10 years. Studies were assessed for the followings: country, model structure 
and simulation method, time horizon, perspective, source of key parameters, results, 
and key drivers determined from sensitivity analysis. Results: Twenty-three stud-
ies were reviewed in details. Markov (6 articles) and decision-tree (8 articles) models 
were adopted, and time horizon were relatively short, ranging from 8 weeks to 5 
years. Thirteen studies included costs of productivity loss. Costs were based on lit-
erature or expert opinion in 21 studies. Utility scores were referred to other studies 
(17 articles). Parameters which became key drivers for these analyses varied among 
studies. cOnclusiOns: Data collection methods adopted in prior studies were con-
sidered applicable to CEA for UC treatment in Japan. Cost data can be obtained not 
only from questionnaire survey to doctors but commercial database. Because evidence 
on utility scores of Japanese population is still limited, further studies will be needed, 
especially on MDD patients in depression, remission, and relapse phase of treatment.
PMH25
EConoMiC AnAlySiS of PAliPEridonE long-ACting ACting injECtAblE 
for CHroniC SCHizoPHrEniA in PortugAl
Maia-Lopes S1, Van Impe K2, Goswami P2, Einarson TR3
1Janssen Cilag Portugal, Barcarena, Portugal, 2Janssen-Cilag GmbH, Neuss, Germany, 3University 
of Toronto, Toronto, ON, Canada
Objectives: Patients with chronic schizophrenia are difficult to manage and costly 
to the health system. The European Medicines Agency has approved paliperidone 
palmitate (PP-LAI; Xeplion®), an atypical antipsychotic depot which is adminis-
tered monthly. However, its pharmacoeconomic profile in Portugal is unknown. 
Therefore, we conducted a cost-effectiveness analysis from the analytic viewpoint 
of the Portuguese National Health Service. MethOds: PP-LAI was compared with 
long acting injectable forms of risperidone (RIS-LAI) and haloperidol (HAL-LAI) as 
well as oral drugs (oral-OLZ) using a 1-year decision tree previously used in Europe 
and adapted to Portugal with guidance from clinical experts. We obtained clinical 
information and costs from literature sources and published lists. Clinical out-
comes included relapses (both requiring and not requiring hospitalization), days 
with relapse, and quality-adjusted life-years (QALYs). Costs were expressed in 
2015 euros. Economic outcomes included a cost-utility (incremental cost/QALY) 
and cost-effectiveness analyses (incremental cost/relapse as well as hospitalization 
avoided). Results: PP-LAI had the lowest rates for all negative events. Respective 
outcomes for PP-LAI, RIS-LAI, HAL-LAI and oral-OLZ included relapse days (37.4, 51.2, 
79.5, 78.0), Emergency Room visits (0.122, 0.168, 0.250, 0.242), hospitalizations (0.288, 
0.394, 0.623, 0.615) and QALYs (0.8227, 0.7985, 0.7585, 0.7609). Expected costs were 
lowest for oral-OLZ (4447€ ), followed by 4474€ for HAL-LAI, 5326€ for PP-LAI, and 
6223€ for RIS-LAI. HAL-LAI and RIS-LAI were both dominated and eliminated from 
further consideration. PP-LAI had an ICER of 14,247€ /QALY gained over oral-OLZ, 
which was considerably below the NICE threshold (≈27,600€ ). In cost-effectiveness 
analyses, PP-LAI had ICERs of 1902€ /relapse avoided and 2626€ /hospitalization 
avoided. Model drivers were hospitalization for HAL-LAI (74%) and oral-OLZ (59%); 
for PP-LAI 49% was due to drug and 39% hospitalization and for RIS-LAI it was 44% 
drug and 44% hospitalization. cOnclusiOns: PP-LAI is cost-effective in Portugal 
when compared with the customary treatments.
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Objectives: As a chronic illness, schizophrenia consumes a vast amount of health-
care resources and is therefore associated with both high direct and indirect health-
care costs. Pervasive suboptimal quality of life coupled with a high economic burden 
renders policy and healthcare decision makers seeking cost-effective treatments. This 
study aimed at evaluating the cost-effectiveness of aripiprazole once-monthly 400mg 
(AOM) versus paliperidone palmitate 50-150mg (PP) in the maintenance treatment 
of schizophrenia based on the QUALIFY study (NCT01795547). MethOds: QUALIFY 
was a 28-week, randomised, open-label, rater-blinded study comparing AOM with PP 
in the maintenance treatment of schizophrenia. Two key outcomes demonstrated 
improvements for AOM vs. PP: Heinrichs-Carpenter Quality of Life Scale (QLS) and 
Clinical Global Impression – Severity (CGI-S). To assess cost-effectiveness, minimal 
clinically important differences (MCIDs) were sought from the literature in the respec-
tive assessment scales. Treatment response was defined as a change from baseline to 
study termination of at least 6 points and 1 point on QLS total score and CGI-S score, 
respectively. Mean treatment specific costs (incl. drug acquisition) were estimated 
using QUALIFY healthcare resource utilisation data. The analysis was conducted from 
a UK perspective considering direct costs only. Results: In the deterministic analysis 
mean total costs per-patient were £2,093 and £2,954 for AOM and PP, respectively 
for people with moderate to severe conditions. The aim of this research was to 
estimate the costs of pharmaceuticals to the Australian public health sector and 
the most frequently prescribed drugs for the three most prevalent mental illnesses: 
depression, anxiety-related, and substance use disorders. MethOds: The National 
Survey of Mental Health and Wellbeing(NSMHWB) has been conducted every 10 
years since 1997, collecting epidemiology and economic impact to Australian soci-
ety. Respondents diagnosed within the preceding 12 months with depression (D), 
anxiety-related disorders (ANX), and substance use disorders (SUB) by ICD-10 in 
NSMHWB 2007 were included in the analysis. The NSMHWB 2007 reported the 
duration and the name of up to five drugs used during the past 12-month period. 
In order to adjust for inflation, 2013-14 reference year was adopted for the unit 
cost of each drug obtained from Pharmaceutical Benefit Scheme (PBS). Results:: 
Around 23% of respondents used medications for a total cost to the society of AUD 
101 million (SE 11.9). Citalopram was the most frequently prescribed drug (17.11%), 
followed by venlafaxine (15.65%), sertraline (14.43%), and temazepam (10.51%). 
Respondents reported with D+ANX+SUB had the highest percentage in use of 
medications (63.85%), followed by D+ANX (44.26%), and D (34.74%). ANX accounted 
for 50% of total medication costs followed by D+ANX at 23.6%. cOnclusiOns:: 
The high prevalence of ANX contributed to the large proportion of medication costs 
for this condition.
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Objectives: Aripiprazole once-monthly (AOM) is a long-acting injectable formula-
tion of aripiprazole, and is approved in Europe for the maintenance treatment of 
schizophrenia after stabilization with oral aripiprazole. The objective of this research 
was to evaluate the cost-effectiveness of AOM versus paliperidone palmitate (PP) in 
the maintenance treatment of schizophrenia in Spain. MethOds: This pharmaco-
economic evaluation was conducted alongside a 28-week, randomized, open-label, 
rater-blinded study comparing AOM 400mg and PP (50-150mg) in stabilized adults 
with schizophrenia. Effectiveness outcomes of the cost-effectiveness analyses (CEA) 
included the changes in Heinrichs-Carpenter Quality of Life Scale (QLS-primary CEA) 
and Clinical Global Impression-Severity (CGI-S) score at week 28. Visits with health-
care providers, out- and in-patient services were collected using a health economic 
assessment questionnaire (HEA). Healthcare services unit costs from the Basque 
Country were used (2014 costs). All patients with at least one valid post-baseline 
HEA were eligible for analysis. Bootstrapped confidence intervals were generated 
from 10,000 simulations, as well as cost-effectiveness acceptability curves. Results: 
Over the total 28-week period, AOM was associated with significantly reduced total 
healthcare costs compared to PP (mean per-patient cost: € 1,935 vs. € 2,475, respec-
tively; p< 0.001). This cost reduction was primarily due to significant reduction in drug 
acquisition costs (€ 1,237 vs. € 1,889; p< 0.001). The other cost aggregates (healthcare 
provider costs, out- and in-patient costs) were not statistically different between drugs 
(p= 0.528, p= 0.102 and p= 0.194, respectively). In the primary CEA, AOM dominated 
PP (being more effective on the QLS scale and less costly). This result was confirmed 
when using CGI-S as effectiveness measure. The cost-effectiveness acceptability 
curves indicated that AOM was the treatment of choice whatever willingness-to-pay 
threshold used. cOnclusiOns: Aripiprazole once-monthly was associated with 
statistically significantly reduced healthcare costs and greater effectiveness com-
pared to paliperidone palmitate in all scenarios, showing its economic value in the 
management of maintenance schizophrenia in Spain.
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Objectives: Information technology aided relapse prevention programme in 
schizophrenia (ITAREPS) is a unique mobile phone-based telemedicine solution 
for weekly remote patient monitoring and disease management of psychotic 
disorders in general, particularly of schizophrenia. RCTs evidence suggests that 
ITAREPS is highly effective in decreasing hospitalization schizophrenia relapses. 
Based on these RCTs, we performed a cost-utility analysis of ITAREPS compared to 
the treatment of schizophrenia without ITAREPS in the Czech Republic. MethOds: 
We developed a 20-year Markov cohort model with yearly cycle length and four 
health states, i.e. without relapse, with non-hospitalization relapse, with hospi-
talization relapse and death. Transition probabilities and resource use were derived 
from the Czech RCT and utilities were derived from published literature. Costs 
were calculated from healthcare payer’s perspective. Costs and outcomes were 
discounted by 3%. Probabilistic sensitivity analysis (PSA) with 3000 iterations was 
performed. Results: Over a 20-year time horizon, ITAREPS compared to non-
ITAREPS brings additional 0.21 QALY (12.33 vs. 12.12). The incremental total costs 
were -€ 5,554 (€ 55,435 vs. € 60,989) for ITAREPS. The insignificantly higher costs of 
ITAREPS service itself (€ 155 in the first and € 120 in subsequent years) are there-
fore vastly offset by savings of hospitalization relapse costs (€ 1,243 vs. € 11,748); 
ITAREPS on average prevents 5 hospitalization relapses in 20-year time horizon 
(0.73 vs. 5.77 hospitalizations) per patient. The results of the PSA show that ITAREPS 
is cost-effective in 93% iterations under the WTP threshold equal to € 0. An exten-
sive scenario analysis confirmed the base-case results, ITAREPS was dominant in 
all scenarios. cOnclusiOns: ITAREPS is a highly cost-effective intervention in 
patients with schizophrenia and it is even a dominant intervention in comparison 
with non-ITAREPS since it is more effective in terms of QALY gained and cheaper 
at the same time. There is even 93% probability of ITAREPS being cost-effective at 
the WTP threshold equal to € 0.
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costs and productivity losses were calculated. Costs data were derived from Russian 
cost-of-illness study of depression and registered maximal drug prices list. The 
outcomes were modelled for 3 years period. Costs were converted to EUROs using 
the average weighted exchange rate in 2014 (1€ = 50.815RUR). Sensitivity analysis 
was performed. Results: Agomelatine appeared to be the dominant therapy in 
comparison with branded fluoxetine, sertraline and escitalopram, which allowed 
achieving maximum clinical outcome and utility (2.148 QALY vs 2.097, 2.133 and 
2.119 QALY, respectively) at the lowest costs (€ 1,932 vs € 2,485, € 2,076 and € 2,454). 
Agomelatine remained dominant strategy even when only direct medical costs 
were included into analysis (€ 943 vs € 1,172, € 1,002 and € 1,290). cOnclusiOns: 
Agomelatine was demonstrated to be the rational choice in comparison with other 
branded antidepressants routinely used in Russian health care settings.
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Objectives: The prevalence of dementia in Singapore is expected to increase with 
an ageing population. With the inclusion of dementia as part of Chronic Disease 
Management Program, more primary care consultations are expected in the poly-
clinic. A Primary Care Dementia Clinic (PCDC) was set up in Ang Mo Kio Polyclinic to 
manage stable patients. The objective of this study is to evaluate the cost-utility of 
dementia care at PCDC compared with specialists’ care at the Memory Clinic (MC) 
and care at other polyclinics. MethOds: Stable dementia patients with a Clinical 
Dementia Rating of 1.0 – 3.0 were recruited for the programme. Costs were measured 
from the societal viewpoint, including both direct and indirect costs. To establish 
cost-utility, EQ-5D was used to calculate QALYs. Cost and utility were measured at 
six-months and one-year. The incremental cost-effectiveness ratio was calculated 
by dividing the difference in costs by the difference in QALYs. Results: A total of 
168 dementia patients were recruited for this study. 55 for the PCDC arm and 113 
from the two comparator groups (MC = 82 & Other Polyclinics = 31). Compared 
with care at the Memory Clinic and standard polyclinic care, PCDC was $2,110 
(vs. MC) and $2,335 (vs. Other Polyclinics) lower respectively at six-months. There 
were no statistical differences in one-year costs and QALYs across both compari-
sons. cOnclusiOns: Our analysis found that dedicated dementia care for stable 
patients at the primary care setting reduces societal cost. Expansion of PCDC could 
greatly reduce societal resources without impacting patients’ quality of life.
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Objectives: To examine the economic burden and health care utilization for patients 
diagnosed with opioid abuse in the U.S. veteran population. MethOds: Patients 
diagnosed with opioid abuse (International Classification of Diseases, 9th Revision, 
Clinical Diagnosis codes 965.0x and 965.8x) were identified using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2007 through September 
30, 2012. The first diagnosis date was designated as the index date. A comparison 
cohort was created including patients without opioid abuse using 1:1 propensity 
score matching to control for age, region, gender, index year and baseline Charlson 
Comorbidity Index score. The index date was chosen randomly for the comparison 
cohort to minimize selection bias. Patients in both cohorts were required to be at least 
age 18 years and have continuous medical and pharmacy benefits 1 year pre- and 
1 year post-index date. Study outcomes including health care costs and utilizations 
were compared between the disease and comparison cohorts based on the matched 
sample. Results: After 1:1 matching, 1,652 patients were included in each cohort, 
and the baseline characteristics were well-balanced. More patients with opioid abuse 
had inpatient stays (92.37% vs. 5.08%, p< 0.0001) and emergency room (ER) (73.85% vs. 
11.38%, p< 0.0001), physician office (96.91% vs. 71.91%, p< 0.0001), outpatient (97.46% vs. 
72.82%, p< 0.0001) and pharmacy visits (89.83% vs. 75.00%, p< 0.0001). Higher all-cause 
health care costs were also observed for patients with opioid abuse, including inpa-
tient ($29,203 vs. $1,394, p< 0.0001), ER ($1,155 vs. $112, p< 0.0001), outpatient ($9,193 
vs. $2,665, p< 0.0001), pharmacy ($1,516 vs. $696, p< 0.0001) and total costs ($39,913 
vs. $4,757, p< 0.0001) than for study subjects without opioid abuse. cOnclusiOns: 
During a period of 12 months, VHA patients diagnosed with opioid abuse reported 
higher health care utilization and costs than their matched controls.
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Objectives: To determine which economic burden outcomes were assessed in 
studies on mental health disorders published in 2014. MethOds: An evidence sur-
veillance process was established based on a systematic search of PubMed, incor-
porating all studies published from 2010 and updated weekly, with a final search on 
1 June 2015. Abstracts identified by the search for costs or resource use outcomes 
in mental health disorders were identified. Articles were included if they reported 
results from a primary research study or economic model. Economic outcomes were 
identified, where possible, from the abstract alone. Results:: The economic burden 
search identified 1,870 articles published in 2014, with 968 meeting the inclusion 
criteria for any disease. Of these, 76 (8%) were in mental health disorders. The most 
commonly researched disorders were drug, tobacco or alcohol abuse (25 articles), 
followed by depression (17), dementia (7) and schizophrenia (8). The USA was the 
most common setting, based on abstract text or author affiliations (31 articles), fol-
(p< 0.001). According to the QLS MCID, 49% of patients receiving AOM were classified 
as responders vs. 42% of patients receiving PP. For the CGI-S assessment, 52% vs. 34% 
were responders for AOM and PP, respectively. In both assessments, AOM was the 
economically dominant therapeutic option over PP. Univariate sensitivity analyses 
confirmed these findings, the main drivers being cost of inpatient and outpatient 
services. cOnclusiOns: AOM was found to provide superior clinical benefits and 
cost savings compared to PP in all analyses, representing good economic value in the 
maintenance treatment of schizophrenia in the UK.
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Objectives: We analyzed cost effectiveness of buprenorphine/naloxone combina-
tion and sustained release (SR) morphine when compared to methadone in patients 
treated for opioid dependence in Slovenia. To compare the expected costs of treatment 
with buprenorphine/naloxone combination and SR morphine, we also performed 
cost-minimization analysis. MethOds: We adapted a micro-simulation decision 
model to the real-life conditions in Slovenia by using locally-specific data for main-
tenance treatment costs of buprenorphine/naloxone, SR morphine, and methadone 
with the average dose of treatment set at 10.68 mg/day for buprenorphine/naloxone, 
592 mg/day for SR morphine, and 82 mg/day for methadone. All other direct costs 
were based on COBRA (Cost-Benefit and Risk Appraisal of Substitution Treatment 
in Routine) study and adjusted to conditions of the local jurisdiction. Clinical effi-
cacy data for all three treatment options were derived from published literature; in 
cost-minimization analysis, we assumed that buprenorphine/naloxone combination 
and SR morphine were clinically equivalent. Main outcome measures were costs, 
gains in quality adjusted life years (QALYs), and incremental cost-effectiveness ratios 
(ICERs). Results: Our model has shown that under the base case scenario, buprenor-
phine/naloxone dominated methadone (by saving € 60 and gaining 0.153 QALY over 
one year); when comparing SR morphine and methadone, the resulting ICER was 
€ 5,434 per QALY. Cost-minimization analysis revealed lower treatment costs with 
buprenorphine/naloxone combination than those with SR morphine by 45% (€ 488 per 
year), with treatment costs of buprenorphine/naloxone and SR morphine accounting 
for 28% and 41% of total direct medical costs, respectively. The sensitivity analysis 
showed robustness of our findings. cOnclusiOns: Results of our study suggest that 
treating patients with buprenorphine/naloxone combination instead of methadone 
or SR morphine appears to be cost-saving in Slovenia. This result is particularly rel-
evant for implementation of treatment guidelines and for those patients who can be 
prescribed as an intervention of choice either buprenorphine/naloxone combination, 
SR morphine or methadone.
PMH28
A SyStEMAtiC rEviEw of ModEl-bASEd EConoMiC EvAluAtionS of 
drug SubStitution tHErAPiES in MAintEnAnCE trEAtMEnt of non-
PrESCriPtion oPioid dEPEndEnCE
Langham S1, Kenworthy JJ2, Dunlop W2, Chetty M1
1PHMR, London, UK, 2Mundipharma International Ltd, Cambridge, UK
Objectives: Opioid dependence is a serious and costly medical condition that 
can occur with regular opioid use. We conducted a systematic review of published 
model-based economic evaluations of drug substitution therapy in treating non-
medical opioid dependence. MethOds: Literature searches were conducted in 
March 2015 in 8 electronic databases and supplemented by hand-searching refer-
ence lists and searches on 6 health technology assessment (HTA) agency websites. 
The selection criteria included: A population dependent on opioids and receiving 
opioid substitution therapy or maintenance therapy. The intervention included any 
pharmacological maintenance therapy and the comparator included any pharmaco-
logical maintenance regimen, including placebo or no treatment. The outcomes and 
study types included health economic models of any type. Results: After removal 
of duplicates, 2,163 citations were retrieved, of which 63 progressed to full-text 
review. Of these, 19 publications of 18 unique models were included in the review. 
These 18 models used a wide range of modelling approaches, including Markov 
models (n= 4), decision tree with Monte Carlo simulations (n= 4), decision analysis 
(n= 3), dynamic transmission models (n= 3), decision tree (n= 1), cohort simulation 
(n= 1), Bayesian (n= 1), and Monte Carlo simulations for sensitivity analysis (n= 1). 
Time horizons ranged from 6 months to a lifetime. The most common evaluation 
was cost-utility analysis reporting cost per quality-adjusted life-year (n= 11), fol-
lowed by cost-effectiveness analysis (n= 4), budget impact analysis/cost comparison 
(n= 2) and cost-benefit analysis (n= 1). Countries modelled were the US (n= 11), UK 
(n= 4), Spain (n= 1), Vietnam (n= 1) and New Zealand (n= 1). A range of perspectives 
were modelled, including societal and healthcare systems. cOnclusiOns: This 
review identified 8 different modelling structures with a range of perspectives, 
time horizons and inputs, illustrating that there is no single preferred approach. 
Further research is needed into the advantages and disadvantages of the different 
modelling approaches in this disease area.
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Objectives: To evaluate the cost effectiveness of agomelatine versus branded 
fluoxetine, sertraline and escitalopram for treatment of major depressive disor-
ders in adults in Russia. MethOds: We have adapted published Markov model 
of major depression disorder. It consisted of 4 different health states (depression, 
remission, well-being and death). Cycle length was 4 weeks. Transition probabili-
ties and utilities were taken from the international published research data. Direct 
